Valuation: Palvella Therapeutics, Inc.

Market Cap 2.21B 1.93B 1.82B 1.65B 3.1B 212B 3.1B 21.74B 8.38B 108B 8.3B 8.12B 348B P/E 2026 *
-23.4x
P/E 2027 * -18.1x
Enterprise Value 2.02B 1.76B 1.66B 1.51B 2.83B 194B 2.84B 19.86B 7.66B 98.57B 7.59B 7.42B 318B EV / Sales 2026 *
-
EV / Sales 2027 * 76.6x
Free-Float
88.41%
Yield 2026 *
-
Yield 2027 * -
1 day+1.89%
1 week+1.13%
Current month+0.54%
1 month+8.00%
3 months+35.64%
6 months+36.36%
Current year+46.57%
1 week 149.2
Extreme 149.2025
156.78
1 month 136.06
Extreme 136.06
157.93
Current year 72.22
Extreme 72.225
161.38
1 year 56.54
Extreme 56.545
161.38
3 years 11.17
Extreme 11.17
161.38
5 years 11.17
Extreme 11.17
161.38
10 years 11.17
Extreme 11.17
161.38
Date Insider Type Main position Quantity % Market Cap. Importance
16/09/26 Exercice

Chief Operating Officer

12,906 0.0896%
15/09/26 Sell

Chairman

-1,777 0.0123%
02/09/26 Exercice

Director

939 0.0065%
Change 5-day change 1-year change 3-year change Capi.($)
+1.89%+1.13%+163.41% - 2.21B
+4.98%+5.73%+54.45%+113.83% 74.33B
-0.71%+0.35%+36.53%+80.52% 62.26B
-0.66%+6.97%+31.36%+23.45% 27.72B
+0.83%-3.43%-16.41%+359.38% 26.42B
+2.02%-0.87%+1.85%-7.92% 24.62B
-1.04%+4.19%+23.38%-11.43% 20.72B
-2.54%-3.36%+149.64%+324.48% 15.01B
-1.95%+1.80%+42.69%+165.15% 14.18B
-5.32%-8.25%-10.53%+823.50% 13.48B
Average -0.25%+0.77%+47.64%+207.88% 28.1B
Weighted average by Cap. +0.80%+2.25%+36.87%+148.89%

Financials

2026 *2027 *
Net sales - 28.87M 25.17M 23.71M 21.59M 40.48M 2.77B 40.53M 284M 109M 1.41B 108M 106M 4.55B
Net income -94.69M -82.56M -77.76M -70.82M -133M -9.07B -133M -931M -359M -4.62B -356M -348M -14.91B -137M -119M -112M -102M -191M -13.08B -192M -1.34B -518M -6.66B -513M -502M -21.5B
Net Debt -191M -166M -157M -143M -267M -18.26B -268M -1.87B -722M -9.3B -716M -700M -30.02B -
Logo Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Employees
-
Date Price Change Volume
21/09/26 $153.41 +1.89% 123,591
18/09/26 $150.56 -2.44% 646,462
17/09/26 $154.32 +1.91% 157,921
16/09/26 $151.43 +0.14% 201,973
15/09/26 $151.22 -0.31% 215,632
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
153.41USD
Average target price
230.53USD
Spread / Average Target
+50.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PVLA Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!